文献速递系统性红斑狼疮

疑似系统性红斑狼疮患者的补体激活及其预测进展为ACR分类SLE的能力

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2019-11-25

本研究评估了细胞结合补体激活产物(CB-CAPs)在疑似系统性红斑狼疮(SLE)患者中的频率及其预测 probable SLE 进展为美国风湿病学会(ACR)分类SLE的作用。结果显示,probable SLE患者中CB-CAPs(28%)或MAP(40%)阳性率高于低补体水平(9%),且MAP评分>0.8可预测18个月内满足第4条ACR分类标准。

要点

  • 在疑似SLE患者中,CB-CAPs和MAP的阳性率显著高于传统血清补体水平。
  • MAP评分>0.8可预测18个月内进展为ACR分类SLE,风险比3.11。
  • 传统补体检测可能低估疑似SLE患者的补体激活状态。

核心结论

  • 部分疑似SLE患者存在补体激活,CB-CAPs和MAP检测阳性率高于传统血清补体蛋白水平。
  • MAP评分>0.8可预测疑似SLE在18个月内进展为ACR分类SLE。

研究设计与样本

  • 纳入92例疑似SLE(满足3条ACR分类标准)、53例已确立SLE(满足ACR和SLICC标准)、原发性干燥综合征及其他风湿病患者,前瞻性随访疑似SLE病例。

主要发现

  • 疑似SLE患者中CB-CAPs阳性率为28%,MAP阳性率为40%,低补体水平为9%(P=0.0001)。
  • 疑似SLE患者中MAP评分>0.8预测18个月内满足第4条ACR标准(风险比3.11,P<0.01)。

关键数值与推荐

  • CB-CAPs阳性率28%,MAP阳性率40%,低补体水平9%,组间比较P=0.0001。
  • MAP评分>0.8预测满足第4条ACR标准,风险比3.11,P<0.01。

临床怎么用

  • 对疑似SLE患者可考虑检测CB-CAPs或MAP以评估补体激活状态。
  • MAP评分>0.8提示进展为ACR分类SLE风险较高,需密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the frequency of cell-bound complement activation products (CB-CAPs) as a marker of complement activation in patients with suspected systemic lupus erythematosus (SLE) and the usefulness of this biomarker as a predictor of the evolution of probable SLE into SLE as classified by the American College of Rheumatology (ACR) criteria. METHODS: Patients in whom SLE was suspected by lupus experts and who fulfilled 3 ACR classification criteria for SLE (probable SLE) were enrolled, along with patients with established SLE as classified by both the ACR and the Systemic Lupus International Collaborating Clinics (SLICC) criteria, patients with primary Sjögren's syndrome (SS), and patients with other rheumatic diseases. Individual CB-CAPs were measured by flow cytometry, and positivity rates were compared to those of commonly assessed biomarkers, including serum complement proteins (C3 and C4) and autoantibodies. The frequency of a positive multianalyte assay panel (MAP), which includes CB-CAPs, was also evaluated. Probable SLE cases were followed up prospectively. RESULTS: The 92 patients with probable SLE were diagnosed more recently than the 53 patients with established SLE, and their use of antirheumatic medications was lower. At the enrollment visit, more patients with probable SLE were positive for CB-CAPs (28%) or MAP (40%) than had low complement levels (9%) (P = 0.0001 for each). In probable SLE, MAP scores of >0.8 at enrollment predicted fulfillment of a fourth ACR criterion within 18 months (hazard ratio 3.11, P < 0.01). CONCLUSION: Complement activation occurs in some patients with probable SLE and can be detected with higher frequency by evaluating CB-CAPs and MAP than by assessing traditional serum complement protein levels. A MAP score above 0.8 predicts transition to classifiable SLE according to ACR criteria.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 31469249. doi:10.1002/art.41093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。